JRH ASI S.A., a Warsaw Stock Exchange–listed investment company and the initiator and organizer of the ORBITEO technology holding, has acquired Series E shares in QVITI S.A. and signed a letter of intent regarding QVITI’s integration into the ORBITEO cluster. The addition of QVITI strengthens ORBITEO’s competencies in neurotechnology and dual-use solutions, including neurorehabilitation, psychophysical support, and cognitive resilience and decision-making efficiency for operators working under high stress.
JRH continues to expand ORBITEO — a newly established dual-use technology platform on the Polish innovation landscape, combining the strengths of companies active in space technologies, artificial intelligence, defence tech, automation, unmanned systems, deeptech, and satellite telecommunications. Since its launch in October 2025, the number of participating companies has been growing rapidly. Among those already onboard are SatRev, Farada Group, Thorium Space, CBRTP, Sygnis S.A., ELQ S.A., Miloo-Electronics, and CampusAI, with ret. Brig. Gen. Sławomir Żakowski, former NATO wing commander, serving as the cluster’s strategic adviser.
The next development step for ORBITEO is the expansion into neurotechnology. JRH has acquired Series E shares in QVITI S.A. and signed a letter of intent to negotiate the company’s formal entry into the cluster.
QVITI is a Polish neurotech/medtech company, active since 2018, developing technologies based on transcranial electrical stimulation (tES) and AI-driven immersive VR therapies. Leveraging the effects of neuroplasticity, QVITI’s solutions are used in high-demand environments — including defence and security — to support cognitive focus, stress resilience, regeneration and decision-making performance.
“In the medical field, our technologies deliver real quality-of-life improvements for patients suffering from chronic pain, phantom limb pain, depression, and soon PTSD, as well as accelerating stroke rehabilitation. The same neuroplasticity mechanisms that aid recovery can be used for neuro-enhancement in military environments — improving focus, stress resistance, training effectiveness and cognitive recovery in soldiers,”
says Bernard Gołko, CEO of QVITI.
QVITI’s solutions are already in use across four continents — in clinics, research centres and home-patient settings — and the company collaborates with leading institutions including Mount Sinai Hospital, Shirley Ryan AbilityLab and Harvard Medical School. Its technologies are protected by an international patent portfolio, and the company plans to debut on NewConnect in 2026, alongside completing its FDA certification for the US therapeutic market.
“In ORBITEO we integrate infrastructure, operational and decision-making technologies. QVITI brings the missing layer — supporting the human operator as the core of the system. We are convinced this domain will be critical in the years ahead for security and technological advantage. This investment fits perfectly with our vision — we are already considering increasing our stake to above 10%,”
says January Ciszewski, Founder and CEO of JRH.
QVITI’s integration into ORBITEO is highly strategic — extending the cluster’s focus beyond “system technologies” to also include human-performance technologies: for operators, soldiers, pilots, analysts, and rescue personnel. This human-centric layer is essential to building fully integrated dual-use solutions that remain effective in real, high-stress operational environments.
“QVITI’s technologies were created at the intersection of science, medicine and real-world therapeutic impact. The same neuroplasticity mechanisms that aid stroke rehabilitation are applicable in high-stress operational environments. ORBITEO is not just a technology partnership for us — it is a shared mission to accelerate innovation where it matters most for security and health,”
adds Bernard Gołko.
The entry of QVITI expands ORBITEO’s development scope into human resilience and health-enhancing technologies, marking another milestone in building a coordinated Polish platform for dual-use innovation — capable of delivering strategic defence-ready solutions for the 21st century.
